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Recombinant Activated Factor VIIa (NovoSeven®)
Off-Label Use Guidelines
By: Farooq Bandali, PharmD
Recombinant activated factor
VII (NovoSeven®) [rFVIIa] is
indicated for the treatment of
bleeding in patients with hemophilia A or B who have developed antibody inhibitors to factor VIII or factor IX. rFVIIa
has a number of characteristics
that make it an appealing candidate for other bleeding disorders
as well. First, because it is not
enzymatically active by itself,
rFVIIa does not appear to induce
systemic activation of the coagulation system. This reduces the
likelihood of potentially dangerous activation of clotting, as may
occur with concentrates that contain activated coagulation factors. Second, its activity is not
affected by circulating inhibitors
such as antithrombin. Lastly, the
absence of the usual transfusiontransmissible infections provides
a safety advantage over plasmaderived coagulation-factor concentrates.
In the last 6 years, there have
been numerous reports in the
literature regarding the offlabeled uses of rFVIIa. These
publications have been in the
form of case reports, case series,
and small randomized trials.

Large, well-designed clinical trials
are lacking. Despite this, there has
been a steady increase in the use
of rFVIIa both in hospitals nationwide as well as at MUSC.
Due to the lack of data, guidelines
were developed for the use of
rFVIIa in specific off-labeled
uses. The overall objectives of the
guidelines are to help guide appropriate use, minimize unwanted
effects, improve the ordering
process, enhance timely administration of rFVIIa, minimize drugrelated errors, and educate healthcare professionals.
The content of these guidelines is
based on available evidence as
well as clinical practice in adult
patients only. Although there are
several reported off-labeled uses,
only guidelines for the four most
common uses of rFVIIa have been
developed, which include the following:
•
•
•
•

Patients with closed-space
bleeding
Patients undergoing cardiothoracic (CT) surgery
Patients undergoing liver
transplantation
Patients status post trauma
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The closed-space bleeding guideline is comprised of 4 categories
including acute intracranial hemorrhage (ICH), ICH secondary to
oral anticoagulants, isolated traumatic head injury, and retroperitoneal bleed.
The criteria for use in CT surgery
includes patients undergoing a CT
procedure (eg, coronary artery bypass grafting, aortic or mitral
valve replacement, ventricular assist device placement, thoracic
aortic surgery, heart transplant)
with coagulopathic bleeding or
refractory blood loss.
In orthotopic liver transplant patients, rFVIIa has 2 indications,
including rescue therapy for patients after significant clotting factor replacement has been attempted and prophylaxis therapy
for patients who have an INR
greater than 2 after induction of
anesthesia has been administered.
Finally, in trauma, it is indicated
for patients who have severe blunt
or penetrating trauma with coagulopathic bleeding and for which
further large transfusion requirements are anticipated.
These guidelines were reviewed
and approved by physicians practicing at MUSC in their respective
areas of expertise and by the Pharmacy and Therapeutic Committee.
The guidelines are available on
the Formulary and Drug Information Resources Web page under
Drug Information Resources and
the Clinician Order Form page
under Guidelines.
References available upon request.
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MUSC-MC Formulary
System Overview
The formulary system is a process whereby the professional
staff, working through the Pharmacy and Therapeutics Committee, evaluates, appraises, and selects medications that are considered to be most useful in patient care. The formulary system
is an important mechanism for
optimizing patient outcomes
while controlling expenditures.
The MUSC-MC Formulary of
Accepted Drugs is a list of approved medications and dosage
forms available for use throughout the Medical Center. The formulary is a tool that helps practitioners make rational drug therapy decisions. After careful review of current medical literature, the Pharmacy and Therapeutics Committee determines
which agents are added to and
deleted from the formulary.
The formulary is accessible at
www.formluaryproductions.com
/musc, and a link can be found
on the MUSC Medical Center
Intranet at www.musc.edu/
medcenter/index.htm. The online
formulary contains medications
and respective formulations that
are approved for use at the
Medical Center, comments regarding restrictions, links to
medication-specific preprinted
order forms, and links to the Micromedex monograph, patient
education leaflet, and PubMed
citations for each medication.
Other items pertinent to the formulary such as medication use
guidelines, charts, and policies

are also located on the online formulary under Drug Information
Resources.
Any attending physician, fellow,
resident, or intern may prescribe
any unrestricted formulary medication listed in the MUSC-MC
Formulary of Accepted Drugs.
Nurse practitioners and physician
assistants may prescribe formulary
medications based on their scope
of practice in accordance with
South Carolina law and based on
the individual collaborative practice agreement that each clinician
has with their supervising physician.
The Pharmacy and Therapeutics
Committee restricts the use of certain medications on the formulary.
The purpose of placing a restriction on a formulary medication is
to ensure patient safety and appropriate utilization.
Medications
may be restricted by physician
status, physician specialty, specific patient care unit, specific disease state, or specific patient
population. Physicians may prescribe formulary restricted medications so long as the condition of
the formulary restriction is met.
Nurse practitioners and physician
assistants may prescribe formulary
restricted medications within the
scope of their practice in accordance with South Carolina law
and based on the individual collaborative practice agreement that
each clinician has with their supervising physician, so long as the
condition of the formulary restriction is met.
Formulary restrictions are noted in
the online formulary and in the
pharmacy order entry system un-
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der each specific medication. Additionally, a cumulative list of restricted medications is available
on the front page of the online formulary.
Authority to dispense most formulary medications is delegated to
the pharmacist by the Director of
Pharmacy Services. However, the
Pharmacy and Therapeutics Committee requires that prior to dispensing high-cost formulary medications, a second-level administrative approval must be obtained. A
high-cost formulary medication is
defined as one in which the acquisition cost for the expected course
of therapy exceeds $5,000. If the
acquisition cost for the expected
course is $5,000 or greater, the
pharmacist processing the order
will contact the Director of Pharmacy Services or the Chair of the
Pharmacy and Therapeutics Committee to obtain second-level administrative approval prior to
processing the order.
Attending-level members of the
medical or dental faculty may request that a medication or dosage
form be added to or deleted from
the formulary. Formulary request
forms may be obtained from the
Drug Information Center at extension 2-3896 or by e-mail
(druginfo@musc.edu). The completed form must be countersigned
by the appropriate department
chair or division chief.
A formulary monograph is then
prepared by the Drug Information
Center staff. Monographs are
based on published medical literature and focus on the efficacy,
safety, tolerability, and economic
impact of the agent. The medica-
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tion is then presented to the
Pharmacy and Therapeutics
Committee. Following the presentation and discussion, a vote is
taken. Actions taken by the
Pharmacy and Therapeutics
Committee are generally given
an effective date on or about the
15th day of the following month.
Any action deemed necessary
for patient safety becomes effective immediately.

guidance for initiating or adjusting
parenteral or enteral nutrition.

Following each meeting, requesters are notified in writing
of the Committee’s actions.
Changes to the formulary are
published each month in Pharmacy and Therapeutics Update.

Drug Information
Services

Clinical Pharmacy
On-call Services
The Department of Pharmacy
Services provides continuous 24hour clinical pharmacy coverage. On weekdays, please consult the pharmacist covering
your service. For nighttime,
weekend, and holiday coverage,
please page the clinical pharmacist on-call.
If you require clinical pharmacy
services and are on a unit that
does not have regular clinical
pharmacy coverage, please page
the clinical pharmacist on-call
or call the Drug Information
Center at extension 2-3896.
The clinical pharmacist on-call
can design and monitor a
patient’s pharmacotherapy regimen, screen for drug-drug interactions, provide pharmacokinetic
consults, follow up on adverse
drug events, provide intensive
patient counseling, and provide

Clinical pharmacy on-call services
are available for adult, pediatric,
psychiatric, and inpatient family
medicine services. To contact a
clinical pharmacist on-call, go to
http://simonweb.musc.edu and
search “clinical” using the on-call
search feature or call the paging
operator at extension 2-2123.

The Drug Information Center provides evidence-based answers to
the professional staff’s medication-related questions.
In 2005, the Drug Information
Center responded to more than
1,200 questions received from
physicians, pharmacists, nurses,
and other health care professionals.
The mission of the Center is to
promote the best practices
regarding medication usage. The
principle activities of the Drug
Information Center include the
following:
•

•

•

•

Providing responses to drug–
related questions that support
patient care and research
activities
Coordinating the Adverse
Drug Event Reporting
Program
Coordinating the Medication
Utilization Evaluation
Program
Preparing formulary
monographs and class reviews
to guide the Pharmacy and
Therapeutics Committee in its
formulary decisions
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•
•

•
•

Providing educational
inservices
Publishing Pharmacy and
Therapetuics Update: Drug
Information for Health Care
Professionals
Developing medication use
policies
Providing therapeutic
alternatives in response to
medication shortages

The Drug Information Center is
open Monday through Friday,
9:00 AM to 5:30 PM.
The
telephone numbers to the Center
are 792-3896 and 792-7625 or you
can email your request to
druginfo@musc.edu.

Required Elements for
Inpatient and Clinic
Medication Orders
For a medication order to be considered complete and valid, the
Medical Executive Committee has
mandated that the following criteria be met:
Regarding Orders for
Adult Patients
•
•
•

•

•

Prohibited abbreviations must
not be used
Date and time order must
be written
Weight in kilograms required
for medications that are dosed
based on weight (eg, chemotherapy)
Medication name
• generic name preferred,
specify salt form (eg, potassium chloride, potassium
phosphate), chemical names
for electrolytes are acceptable,
except for MgSO4
Dose
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•

•

•
•

•
•

Dosage units
• metric units only, do not
use ampules, tablets, bottles
as the only dosage unit. If
applicable, specify the concentration (eg, mg/mL)
Diluent
• specify if requiring diluent other than the standard
(ie, 5% dextrose or 0.9%
NaCl)
Route of administration
Frequency or interval
• all orders for PRN medications must include an interval and an indication, do not
use range orders with variable dosing frequencies
(eg, q 4 - 6 hours)
Signature/credentials
Pager number of prescriber
Regarding Orders for
Pediatric Patients
[< 17 years of age
(except for obstetric patients)]

•
•
•
•

•

Prohibited abbreviations
must not be used
Date and time order must be
written
Weight in kilograms or
grams
Medication name
• generic name preferred,
specify salt form (eg, potassium chloride, potassium
phosphate), chemical names
for electrolytes are acceptable, except for MgSO4
Dose
• dose/kg/interval required
for all patients weighing less
than 40 kg (eg, mg/kg/dose
or mg/kg/day), for combination medications, the dose/
kg/interval should be specified for one of the medications in the combination, ele-

•

•

•
•

•
•

mental preparations (eg, iron,
zinc) should be ordered based
on the desired dose of the element, not the salt
Dosage units
• metric units only, do not
use ampules, tablets, bottles as
the only dosage unit. If applicable, specify the concentration (eg, mg/mL)
Diluent
• specify if requiring diluent
other than the standard (ie, 5%
dextrose or 0.9% NaCl )
Route of administration
Frequency or interval
• all orders for PRN medications must include an interval
and an indication, do not use
range orders with variable
dosing frequencies (eg, q 4 - 6
hours)
Signature/credentials
Pager number of prescriber

For more detailed information regarding medication orders, please
refer to the medication orders policy C-78 located in the MUSC
Medical Center Clinical Policy
Manual. This manual may be accessed online at www.musc.edu/
medcenter/policy/Med/
clintoc.html.

Online Adverse Drug
Reaction Reporting
Practitioners are urged to use the
University HealthSystem Consortium Patient Safety Net to report
potential ADRs. To access the
reporting system click on the
UHC PSN desktop icon located on
all LYNX work stations and follow the menu-driven instructions.
Please include all pertinent details

Page
Page3 5

related to the occurrence including
suspect medication(s), dose(s),
clinical presentation, description
of how the ADR was managed,
and patient outcome.

Did You Know...
The Food and Drug Administration (FDA) has released a Public
Health Advisory regarding important new safety information about
taking 5-hydroxytryptamine receptor agonists (ie, triptans) concomitantly with selective serotonin reuptake inhibitors (SSRIs)
and selective serotonin and norepinephrine reuptake inhibitors
(SNRIs) [Table 1].
The combination may result in
life-threatening serotonin syndrome, and is most likely to occur
when starting or increasing the
dose of a triptan, SSRI, or SNRI.
Signs and symptoms of serotonin
syndrome include restlessness,
hallucinations, loss of coordination, tachycardia, rapid changes in
blood pressure, hyperpyrexia,
overactive reflexes, nausea, vomiting, and diarrhea. FDA has requested that the prescribing information for each of the medications
be updated to warn of the possibility of serotonin syndrome when
these medications are taken concomitantly.

Formulary Update
The Pharmacy and Therapeutics
Committee recently approved the
following formulary changes:
Additions:
Effective July 1, 2006
NovoLog® Mix 70/30
100-units/10-mL vials
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Table 1. Medications that are Classified as a SSRI,

SSNRI, or Triptans
SSRIs
• Citalopram (Celexa®)*
• Escitalopram
®

•
•
•
•
•

(Lexapro )
Fluoxetine (Prozac®)
Fluoxetine/olanzapine
(Symbyax®)*
Fluvoxamine
(various)
Paroxetine (Paxil®)
Sertraline (Zoloft®)

SNRIs
• Duloxetine

(Cymbalta®)*
• Venlafaxine
(Effexor®)

Triptans
Almotriptan (Axert®)*
Eletriptan (Relpax®)*
Frovatriptan (Frova®)*
Naratriptan (Amerge®)*
Rizatriptan (Maxalt®,
Maxalt®-MLT)*
• Sumatriptan (Imitrex®)
• Zolmitriptan (Zomig®,
Zomig®-ZMT)*
•
•
•
•
•

* Nonformulary Status

Effective July 17, 2006
Pregabalin (Lyrica®)
50-, 75-, 100-, and 150-mg
capsules

Vitamin A (various)
10,000- and 15,000-unit tablets

Addition with restriction:
Effective July 17, 2006
Risperidone long-acting
injection (Risperdal® Consta®)
25-, 37.5-, and 50-mg
pre-filled syringes

Deletions:
Effective July 1, 2006
Novolin® 70/30
100-units/10 mL vials

Restriction Added:
Effective July 1, 2006
As part of the initiative to limit
the use of regular insulin
(Novolin® R), the subcutaneous
administration of this product
will be restricted to the Diabetes
Management Service.
100-units/10-mL vials
Change in Restriction:
The use of factor VIIa recombinant (rFVIIa) for closed-space
injury, cardiothoracic surgery,
liver transplantation, and trauma
will be restricted to attending
physicians and fellows.
Line-extensions:
Effective July 17, 2006
Hyaluronidase (Vitrase®)
200-units/mL injection

Quetiapine fumarate (Seroquel®)
50- and 400-mg tablets

Effective July 17, 2006
Vitamin A (various)
25,000- and 50,000-unit capsules
Zalcitabine (Hivid®)
0.375- and 0.75-mg tablets
Stavudine (Zerit®)
15-, 20-, 30-, and 40-mg
capsules; 1-mg/mL injection
Delavirdine mesylate
(Rescriptor®)
100-mg tablets
Amprenavir (Agenerase®)
50-mg tablets; 15-mg/mL
solution
Indinavir sulfate (Crixivan®)
200- and 400-mg capsules
Saquinavir mesylate (Invirase®)
200-mg capsules
Saquinavir (Fortovase®)
200-mg capsules

